血液肿瘤学中的诊疗一体化
本文为继续教育综述,概述血液肿瘤学诊疗一体化的进展:2000年代初抗体介导放射免疫治疗获FDA批准,包括90Y-替伊莫单抗和131I-托西莫单抗;SIERRA III期试验中期结果显示131I-抗CD45抗体(Iomab-B)对难治或复发急性髓系白血病有益;近十年C-X-C趋化因子受体4导向分子影像扩展了诊疗一体化,其PET/CT可筛选β发射放射性配体治疗候选者并提供抗淋巴瘤疗效及骨髓龛清除,为干细胞移植创造条件。
要点
- 90Y-替伊莫单抗和131I-托西莫单抗已获FDA批准用于特定淋巴瘤。
- SIERRA III期试验中期结果显示Iomab-B对难治或复发急性髓系白血病有益。
- C-X-C趋化因子受体4导向PET/CT可筛选β发射放射性配体治疗候选者。
核心结论
- 血液肿瘤学诊疗一体化已从抗体介导放射免疫治疗扩展至C-X-C趋化因子受体4导向分子影像与放射性配体治疗。
研究设计与样本
- 继续教育综述,概述血液肿瘤学诊疗一体化的当前进展并突出新兴临床应用。
主要发现
- 2000年代初重大临床试验提供抗体介导放射免疫治疗对血液肿瘤有利结局的证据,并导致FDA批准。
- SIERRA III期试验首次中期结果报告131I-抗CD45抗体(Iomab-B)对难治或复发急性髓系白血病有益。
- C-X-C趋化因子受体4导向PET/CT除提高可疑病灶检出率外,还可筛选针对淋巴瘤细胞表面同一趋化因子受体的β发射放射性配体治疗候选者。
- 影像导向治疗策略在T细胞或B细胞淋巴瘤患者中提供稳健抗淋巴瘤疗效及所需骨髓龛清除。
- 放射性配体治疗介导的骨髓消融作为治疗计划组成部分,可使患者衔接干细胞移植并在后续治疗中成功植入。
关键数值与推荐
- 90Y-替伊莫单抗用于难治性低级别滤泡性淋巴瘤或转化性B细胞非霍奇金淋巴瘤。
- 131I-托西莫单抗用于利妥昔单抗难治性滤泡性淋巴瘤。
- 131I-抗CD45抗体(Iomab-B)用于难治或复发急性髓系白血病(SIERRA III期试验中期结果)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the early 2000s, major clinical trials provided evidence of a favorable outcome from antibody-mediated radioimmunotherapy for hematologic neoplasms, which then led to Food and Drug Administration approval. For instance, the theranostic armamentarium for the referring hematooncologist now includes 90Y-ibritumomab tiuxetan for refractory low-grade follicular lymphoma or transformed B-cell non-Hodgkin lymphoma, as well as 131I-tositumomab for rituximab-refractory follicular lymphoma. Moreover, the first interim results of the SIERRA phase III trial reported beneficial effects from the use of 131I-anti-CD45 antibodies (Iomab-B) in refractory or relapsed acute myeloid leukemia. During the last decade, the concept of theranostics in hematooncology has been further expanded by C-X-C motif chemokine receptor 4-directed molecular imaging. Beyond improved detection rates of putative sites of disease, C-X-C motif chemokine receptor 4-directed PET/CT also selects candidates for radioligand therapy using β-emitting radioisotopes targeting the identical chemokine receptor on the lymphoma cell surface. Such image-piloted therapeutic strategies provided robust antilymphoma efficacy, along with desired eradication of the bone marrow niche, such as in patients with T- or B-cell lymphoma. As an integral part of the treatment plan, such radioligand therapy-mediated myeloablation also allows one to line up patients for stem cell transplantation, which leads to successful engraftment during the further treatment course. In this continuing education article, we provide an overview of the current advent of theranostics in hematooncology and highlight emerging clinical applications.
引用
- Buck AK, Serfling SE, Kraus S, et al. Theranostics in Hematooncology. J Nucl Med. 2023. PMID: 37290799. doi:10.2967/jnumed.122.265199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。